Cancer Genomics - Cancer PHGKB -

Specific PHGKB|Cancer|PHGKB

Cancer Genomics

- Cancer PHGKB -

What's New

Last Posted: Nov 16, 2018

---

• NCI-MATCH Update: More Labs, New Arms, and Initial Findings  
  NCI, November 15, 2018
• UBE2D1 RNA Expression Was an Independent Unfavorable Prognostic Indicator in Lung Adenocarcinoma, but Not in Lung Squamous Cell Carcinoma.  
  Hou Liyan et al. Disease markers 2018 20184108919
• A DNA Methylation-Based Test for Breast Cancer Detection in Circulating Cell-Free DNA.  
  Salta Sofia et al. Journal of clinical medicine 2018 Nov 7(11)
• A Recurrent BRCA2 Mutation Explains the Majority of Hereditary Breast and Ovarian Cancer Syndrome Cases in Puerto Rico.  
  Diaz-Zabala Hector J et al. Cancers 2018 Nov 10(11)
• Applying new Magee equations for predicting the Oncotype Dx recurrence score.  
  Sughayer Maher et al. Breast cancer (Tokyo, Japan) 2018 Sep 25(5) 597-604
• Cancer Evolution as the New Frontier of Precision Medicine.  
  Curigliano Giuseppe et al. Handbook of experimental pharmacology 2018 Nov
• Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use.  
  Bacher Ulrike et al. Blood cancer journal 2018 Nov 8(11) 113
• Concordance with BRCA1/2 testing guidelines among women in The Health of Women (HOW) Study ® .  
  Silver Michelle I et al. Breast cancer research and treatment 2018 Nov
• CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.  
  Drögemöller Britt I et al. Breast cancer research and treatment 2018 Nov
• Direct-to-Consumer Tests with Marketing Authorization  
  FDA, 2018